Michael P. Link

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation”.

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

Journal of Clinical Oncology(2021)10.1200/jco.20.03286

N/A

2.4DataRank · unranked

59 citations

Michael P. Link, Amy L. Billett, Jamie E. Flerlage, John T. Lucas, Belinda N. Mandrell +16 more

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood(2022)10.1182/blood.2022015851

N/A

0DataRank · unranked

1528 citations

Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson +68 more

Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

Genetics in Medicine(2022)10.1016/j.gim.2022.05.007

N/A

0DataRank · unranked

278 citations

Ludwine Messiaen, Eric Legius, Patrice Pancza, Robert A. Avery, Jaishri O. Blakeley +79 more

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

Nature(2023)10.1038/s41586-023-06903-x

N/A

0DataRank · unranked

111 citations

Mohammad Shahrokh Esfahani, Andrea Garofalo, Michael Y. Li, Cédric Rossi, Tim Flerlage +44 more

Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90

Blood Advances(2023)10.1182/bloodadvances.2023010944

N/A

0DataRank · unranked

0 citations

Yiwang Zhou, Ying Zheng, Lianna J. Marks, Alison M. Friedmann, Howard J. Weinstein +3 more

Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era

Blood Advances(2025)10.1182/bloodadvances.2024014745

N/A

0DataRank · unranked

7 citations

Victor Ritter, Jennifer E. Agrusa, Kala Y. Kamdar, Julie Rivers, Rebecca Gardner +21 more